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Abstract
Canine mast cell tumours (MCT) are 
malignant neoplasms, and are possibly 
the most common skin cancers in dogs. A 
precise diagnosis is fundamental in making 
appropriate therapeutic decisions and thus 
avoiding a poor prognosis, which frequently 
ends in rapid death. In this study, data from 
59 dogs diagnosed with mast cell tumours 
of three malignancy grades were selected 
and clinical follow-up was carried out over 
47 months to determine the relationship 
between the decision to perform surgery, 
the degree of tumour malignancy and the 
survival status of the animals. The results 
showed that the majority of affected animals 
died as a result of the disease, some of 
which had undergone surgical treatment. 
The surviving dogs were diagnosed mostly 
with mast cell tumours of low malignancy. 
There was no significant association between 
surgery and survival. We conclude that 
cytological analysis is fundamental for an 
early diagnosis of canine MCTs and enable a 
more accurate prognosis to guide subsequent 
treatment. We discuss the need for clear 
malignancy criteria allowing for adequate 
cytological classification of these lesions.
Key words: cancer; cytology criteria; 
diagnosis
Introduction
A mast cell tumour is a malignant 
skin neoplasm that can affect dogs of any 
age, although it occurs often in animals 
from 8 to 10 years old. It can develop 
anywhere on the body surface but most 
commonly arises on the extremities 
(especially the thigh), ventral abdomen, 
and thorax (O’Keefe, 1990). The external 
appearance of an MCT corresponds to a 
raised and nodular mass, soft or solid, 
that is generally well circumscribed 
with a diameter ranging from 1–10 
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centimetres (occasionally larger), 
although these lesions can also present as 
an oedematous, poorly defined swelling 
(Dobson and Scase, 2007). Histologically 
there has been an evolution in the 
interpretation of morphological changes 
in an MCT. Initially, they appear in 
three grades (Lee Gross et al., 2005). 
Grade I refers to a solitary tumour 
confined to the dermis without lymph 
node involvement, round or ovoid mast 
cells of uniform size and well-defined 
cytoplasmic borders, uniformly spherical 
nuclei, large granules in the cytoplasm, 
and uniformly distributed cells separated 
by collagen fibres. An intermediate 
grade II MCT is a solitary tumour with 
regional lymph node involvement and 
neoplastic cell infiltration in the deep 
dermis. These lesions are similar to those 
of grade I but have variable cell sizes, 
cytoplasmic borders that are not always 
well defined, and large and slightly 
vesicular nuclei. Grade III or anaplastic 
MCTs are characterized by multiple 
dermal tumours that can affect the lymph 
nodes. These cells are distributed in a 
way that forms large masses of neoplastic 
tissue with marked pleomorphism 
and have large nuclei with irregular 
internal vesicles and generally one to 
three prominent nucleoli. Sometimes 
very numerous mitotic figures appear in 
grade III MCTs, and the cytoplasm has 
indefinite edges (Patnaik et al., 1984).
In some cases, it is difficult to 
distinguishing grade II MCTs from the 
other categories. Taking the biological 
behaviour of these neoplasms into 
account, Kiupel et al. (2011) proposed a 
new classification involving two stages 
of malignancy, i.e. a low degree or a 
high degree of malignancy. This grading 
system has since been adopted by a 
number of pathologists, although the old 
classification is still used. Cytologically, 
there is no specific classification for the 
different grades of MCT (Pedraza et 
al., 2011), though in this regard Kiupel 
and Camus, (2019) proposed that their 
two histopathological stage approach 
has utility since many of its parameters 
coincide between histology and 
pathology. Cytologically, a canine MCT 
is a round cell neoplasm that can also be 
staged as a well, moderately or poorly 
differentiated lesion (Raskin, 2010). The 
behaviour of canine MCTs varies from 
animal to animal, though these lesions 
should be considered malignant in all 
cases. These tumours generally start 
to spread to the regional lymph nodes, 
spleen, liver, kidneys, lungs, and heart. 
Dogs affected by MCTs also develop 
gastroduodenal ulcers at a relatively high 
frequency due to the release of vasoactive 
amine from malignant mast cells (Dobson 
and Scase, 2007). The most effective 
treatment is surgery, though only if 
conducted by an experienced surgeon, 
as a lack of expertise with this procedure 
will likely result in a very poor outcome 
(Simpson et al., 2004). Some authors 
have reported that chemotherapy can 
maintain animals in a reasonably stable 
condition for a few months, though this 
will not be curative (Grier et al., 1995). 
A clinical follow-up of the survival 
outcomes of dogs affected by MCTs of 
different malignancy grades, diagnosed 
by cytology and histopathology, is 
described in this study.
Material and Methods
This was a retrospective descriptive 
study of 59 dogs diagnosed with MCT 
over a two-year period from January 
2016 and January 2018 at the Veterinary 
Pathology Laboratory of the Universidad 
de Caldas, Colombia. Survival monitoring 
was carried out until December 2019. The 
animals were presented at the veterinary 
hospital or other regional clinics as part 
of an outpatient care routine. In most 
cases, the neoplasia diagnosis was made 
by cytology (fine needle aspiration) in 
which slides were air-dried and stained 
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with Kwik-Diff® and Giemsa. MCTs were 
staged as being of low-grade, moderate 
or high-grade malignancy. Table 1 
summarizes the cytological criteria 
used for the animals, as described by 
Raskin, (2010) and Pedraza et al. (2011). 
Additionally, all cases were reviewed by 
histopathology, i.e. tissues were stained 
with haematoxylin-eosin (H&E) and 
then stained with Giemsa. Tumours were 
graded as grade I, II, or III, as suggested 
by Patnaik, (1984). 
The cases were reviewed by 
light microscopy (both cytology and 
histopathology) by two pathologists, 
and only cases with no controversy 
regarding the diagnosis were included in 
this present study. The medical records 
of each animal were reviewed and data 
were collected on breed, sex, age, and 
history of presentation of MCT. We also 
collected the dates of diagnosis and 
surgery, as applicable, and whether the 
dog was alive at the cut-off date for the 
investigation.
Since cases were approved by 
different veterinarians and veterinary 
surgeons and animals were attended to 
at different times, it was not possible 
to obtain details of the chemotherapy 
protocols that some animals underwent 
or the surgical techniques used in some 
cases. It was only known that most 
cases were treated by surgical excision 
and regional adenectomy was not 
considered in any of these animals. For 
statistical analysis, an adjusted binary 
logistic regression model was used, 
where the dependent variable was 
survival and the independent variables 
were the performance of surgery and the 
MCT grade. SPSS version 23 software 
was used to conduct the statistical 
comparisons.
Results
Most of the dogs affected by MCT 
enrolled in this study (46/59; 78%) were 
of a defined breed, including Labradors, 
French poodles and the Pitbull terriers. 
Eleven dogs (18.6%) were mongrel breeds 
and no breeding data were available for 
the remaining 2 animals (3.4%). At the 
time of admission, the youngest dog 
was one year of age and the oldest was 
14 years old. Most of the affected animals 
were of mid-age i.e. 15 (25.4%) were 
under 5 years, 35 (59.3%) were between 
5 and 10 years and 9 (15.3%) were over 
10 years. Almost half (29) of the animals 
were female.
Table 1. Morphologic criteria currently used for grading canine mast cell tumours in cytopathology 
(Pedraza et al., 2011)
Cytologic 













Moderate increase in nuclear-cytoplasmic ratio







Marked increase in nuclear-cytoplasmic ratio
Increased atypical mitotic figures 
Multinucleated cells
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With regard to the MCT diagnoses in 
our current canine series, the majority of 
cases (38/59; 64.4%) showed first grade 
malignancy (grade I), 14 (23.7%) showed 
grade II and 7 (11.9%) displayed grade 
III lesions (Table 2). It was determined 
that 31 of the animals (52.5%) died as a 
consequence of the disease and 25 (42.4%) 
were alive at the end of this study, with no 
survival data available for the remaining 
3 cases (5.1%). Of the 38 animals affected 
by a grade I MCT, 17 (44.7%) died as a 
result of the disease, 20 (52.6%) were alive 
at the end of the study period and no data 
were available for one animal. Of the 14 
dogs affected by grade II MCT, 7 (50%) 
died, 5 (35.7%) survived and 2 had no 
data. For the 7 animals affected by grade 
III MCT, the mortality rate was 100% 
during the study period (Table 2).
With regard to the mortality rates and 
the decision to perform surgery, 13/38 
(34%) dogs with a grade I MCT died 
between 120 and 180 days after surgery 
whereas 4 animals (10.5%) died of the 
disease, with some receiving cytotoxic 
drugs. There were no data available for 
one animal. The remaining animals with 
a grade I lesion (20/38; 52.6%) were living 
at the end of the study and the majority 
(11) did not undergo surgery or medical 
treatment (except for one case treated 
with glucocorticoids). Four of the animals 
(4/14; 28.6%) with a grade II MCT died 
(maximum 180 days) after surgery whilst 
3 cases (21.4%) died from the disease 
without having undergone surgical 
treatment. Two grade II cases had no data 
and the remaining 5 animals (35.7%) were 
still living at the end of the study (three 
with post-surgical follow-up between 690 
and 750 days and two without surgery 
who had between 1260 and 1290 days 
of clinical follow-up). The dogs with a 
grade III MCT all died between 60 and 
120 days after diagnosis, with 5 animals 
(71.4%) dying after surgery and the 
remaining 2 dogs (28.8%) succumbing to 
the severity of the disease without having 
the opportunity to receive any type of 
treatment (Figure 1).
The animal observed for the least time 
in our current series was a 10-year-old 
female Pointer that survived for 690 days 
Table 2. Survival outcomes among the canine subjects by the end of the study













Figure 1a. Cutaneous MCT initially seen as 
solitary lump in underneath the trunk skin; b. 
Presence of axillary lymph node metastases in 
a grade II MCT; c. Cytological photomicrograph 
of undifferentiated mast cell tumour stained 
with Wright; in the upper right box, binucleated 
cells (white arrow) and multinucleate cells (black 
arrow) stained with Giemsa; d. Histological 
picture of muscle tissue underlying grade III MCT 
showing malignant cell infiltrate
Clinical follow-up of canine mast cell tumour cases diagnosed by cytology and histopathology
Kliničko praćenje slučajeva mastocitoma u pasa koji su dijagnosticirani citološki i histopatološki
VETERINARSKA STANICA 52 (4), 397-403, 2021. 401
after excision of a grade II MCT from the 
belly. The longest observation time was 
for a three-year-old female Pitbull that 
survived for 1290 days after excision of 
a soft mass, grade I MCT located in the 
skin of the right flank that had shown 
progressive growth of approximately 
one year. The longest surviving animal 
in our current cohort was a male Pinscher 
with a grade I MCT in the scrotum, who 
died as a consequence of systemic disease 
31 months after having undergone an 
orchiectomy.
Among the dogs in our present series 
that did not undergo surgery, an 8-year-
old female Labrador that presented with 
a small mass in the interdigital area of 
the left thoracic limb, a grade I MCT, had 
the shortest survival time (1230 days). 
Another female Labrador of 7 years of 
age who had masses in the mammary 
gland and a grade I MCT in the right 
pelvic limb was still living without 
having undergone surgery after 1320 
days of clinical follow-up.
Necropsy was performed on two 
animals diagnosed with grade III MCT 
and revealed metastatic processes in the 
regional lymph nodes, and in the spleen 
in one case. No metastases to the lung 
or other organs were observed (Figure 
2). Overall, there was no significant 
association found between surgery and 
survival outcomes (P = 0.08).
Discussion
Neoplasms of the cutaneous system 
are frequent in dogs, with MCT being the 
most common, followed by the transmissi-
ble venereal tumour and other round cell 
neoplasms such as histiocytoma and basal 
cell epithelioma (Duncan and Prasse 1979; 
Ferreira De La Cuesta, 2003). Canine MCT 
has a somewhat benign clinical appear-
ance but is a highly aggressive tumour that 
almost always results in the death of the 
animal (Welle et al., 2008). In the present 
study of canine MCT cases, there appeared 
to be a disease predilection for dogs of a 
defined breed, regardless of sex, similar to 
reports by Shoop et al. (2015). We also ob-
served that most animals affected by MCT 
in our current cohort died, with a 100% 
mortality rate seen for the grade III cas-
es. In contrast, a number of animals with 
a grade I MCT (i.e. a well-differentiated 
tumour) were still living at the end of the 
study period. It is possible that the better 
survival rates in grade I cases may be relat-
ed to the decision to not intervene surgical-
ly with some of the higher grade tumours, 
and to operate only in cases with a low 
degree of malignancy and at sites that en-
able wide surgical margins. However, this 
could not be fully elucidated in this study. 
Notwithstanding that issue, since MCT is 
an aggressive neoplasm that can invade 
underlying tissues and metastasize to oth-
er organs, a moderately invasive method 
for making an initial diagnosis such as fine 
needle aspiration cytology (FNAC) is es-
sential in order not to stimulate the growth 
of these lesions and also to avoid surgery 
when the site of the tumour is difficult to 
access. This could be a decisive determi-
nant of the animal’s survival time.
None of the dogs in our present study 
series appeared to show any signs of a 
cutaneous mass as a underlying reason 
for their initial consultation. However, 
it is always important to investigate 
for possible non-cutaneous clinical 
signs, such as gastric ulcers caused 
by the release of histamine, leading to 
Figure 2. Survival outcomes (with and without 
surgery) for canine subjects with different grades 
of MCT. The mortality rate was 100% for grade III 
MCT cases
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vomiting, diarrhoea and anorexia, as 
well as alterations in the coagulation 
process (MACY and MACEWEN, 1989; 
Rogers, 1993; Lemarié et al., 1995). In 
our experience, cytology is essential 
for the rapid and effective diagnosis of 
canine MCT, and this may well improve 
survival outcomes by assisting with the 
decision regarding surgery or medical 
management. According to the current 
literature, once MCT is diagnosed, a new 
physical examination is recommended to 
determine whether there is any regional 
lymph node involvement and to rule 
out the presence of splenomegaly or 
hepatomegaly, which can be evidenced 
by radiography or ultrasound, thus 
excluding systemic neoplasia (O’Keefe, 
1990). None of the animals in our current 
investigation showed lymph node 
involvement after a physical examination, 
and cytology samples were therefore not 
sent for this type of tissue. Although some 
authors have suggested that cytology is a 
science in itself with independent criteria 
(Thrusfield, 1995; Ghisleni et al., 2006), we 
contend that all diagnostic tests should 
be compared with a gold standard to 
confirm their accuracy. Thus, we believe 
that a less subjective and more reliable 
cytological classification system is 
required, including previously suggested 
additional criteria for malignancy that 
are commonly used in human medicine 
(Pedraza et al., 2011).
In our present investigation, 
some dogs with low-grade MCT that 
underwent surgery were still living at the 
time of verifying their clinical condition. 
This could be related to the prior 
recommendation of Martínez-De-Merlo 
(2000) that surgical excision remains 
the treatment of choice for canine MCT, 
as long as the masses are well defined 
and delimited. Other recommendations 
include removing the closest lymph 
node and skin three centimetres from 
each side of the tumour to a depth of one 
centimetre (Simpson et al., 2004). It must 
be noted that locally invasive MCT may 
be difficult or impossible to completely 
eliminate in some places, such as the oral 
mucosa, mouth, nose, thoracic and pelvic 
limbs due to the limited surgical margin 
(Davies et al., 2004). It is possible that 
some of the animals included in this study 
did not undergo surgery precisely due to 
the difficulty of the surgical approach. 
Although this could not be conclusively 
demonstrated, this could be related to a 
greater probability of survival.
Conclusions
Mast cell tumour is an aggressive 
neoplasm with variable biological 
behaviour. An early and non-invasive 
diagnosis facilitates decision-making 
regarding treatment. Cytology is a 
fast and inexpensive technique that 
showed great utility for the diagnosis in 
cases of canine MCT and possibly, the 
therapeutic decisions associated with its 
implementation. This was directly related 
to the increase in the survival period in 
some of the cases presented here.
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Mastocitomi u pasa (MCT) maligne su 
neoplazije te vjerojatno najčešći oblik raka 
kože u pasa. Precizna dijagnoza ključna 
je za donošenje ispravnih odluka u svezi 
liječenja, a tako i za izbjegavanje loših 
prognoza koje često završavaju brzom 
smrću. U ovom istraživanju odabrani 
su podatci 59 pasa kojima je prethodno 
dijagnosticiran mastocitom tri različita 
stupnja malignosti te je provedeno kliničko 
praćenje tijekom 47 mjeseci za ustvrđivanje 
odnosa između odluke o operaciji, stupnja 
malignosti tumora i statusa preživljavanja 
životinja. Rezultati su pokazali da je većina 
oboljelih životinja, od kojih su neke bile 
podvrgnute operaciji, uginula uslijed 
bolesti. Psima koji su preživjeli uglavnom je 
dijagnosticiran tumor niske malignosti. Nije 
bilo značajne povezanosti između operacije i 
preživljavanja. Zaključujemo da je citološka 
analiza presudna za ranu dijagnozu MCT-a u 
pasa i za omogućavanje preciznije prognoze 
koja će voditi daljnje liječenje. Raspravljamo 
o potrebi uspostave jasnih kriterija malignosti 
da bi se omogućila prikladna citološka 
klasifikacija ovih lezija.
Ključne riječi: rak, citološki kriteriji, 
dijagnoza
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